Compositions comprising hiv envelopes to induce ch235 lineage antibodies
AssigneesDuke University, Los Alamos National Security, LLC
InventorsBarton F. HAYNES, Mattia BONSIGNORI, Hua-Xin LIAO, Bette T. KORBER, Peter T. HRABER, Kevin SAUNDERS
Life of this patent
Estimating the term…
Abstract
In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.
Claims19
A recombinant HIV-1 envelope polypeptide from Table 1, wherein the polypeptide is a non-naturally occurring protomer designed to form an envelope trimer.
A recombinant trimer comprising three identical protomers of an envelope from Table 1.
A method of inducing an immune response in a subject comprising administering a composition comprising any suitable form of a nucleic acid(s) encoding an HIV-1 envelope(s) in an amount sufficient to induce an immune response from one or more of the following groups:
- (a) envelopes M5, M11, w20.14, w30.20, w30.12, and w136.B18 (Selection F, e.g. listed in FIG. 18A) or any combination thereof,
- (b) envelopes M5, w30.25, w53.25, and w53.29 (Selection G, e.g. FIG. 20) or any combination thereof;
- (c) envelopes M5, w30.20, w20.14, and w30.12 (Selection H, e.g. FIG. 21) or any combination thereof,
- and wherein the administration step can alternatively, or in addition, comprise administering an HIV-1 polypeptide(s) in an amount sufficient to induce an immune response from one or more of the following groups:
- (a) envelopes M5, M11, w20.14, w30.20, w30.12, and w136.B18 (Selection F, e.g. listed in FIG. 18A) or any combination thereof,
- (b) envelopes M5, w30.25, w53.25, and w53.29 (Selection G, e.g. FIG. 20) or any combination thereof;
- (c) envelopes M5, w30.20, w20.14, and w30.12 (Selection H, e.g. FIG. 21) or any combination thereof.
Dependencies are inferred from the claim text.